← Leaderboards
Alan P. Kozikowski
University Of Illinois At Chicago
$10,594,236
Attributed
$13,237,911
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2008–18$2.5M$1.9M$1.3M$625K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$13,237,911 · 9
By mechanism
R01$7,763,409 · 5
U19$4,499,113 · 1
R43$582,726 · 2
R41$392,663 · 1
Top collaborators
- Ludo Van Den Bosch5 shared
- Bryan L Roth3 shared
- William C Wetsel2 shared
- Barbara J. Caldarone1 shared
- Marcia N Gordon1 shared
- David Morgan1 shared
Most similar at University Of Illinois At Chicago
Same institution · by research overlap
- Ludo Van Den Bosch$947,449
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignProgramsPharmaceutical PreparationsBehaviorCellsIn VivoFamilyLeadIn VitroBaseAdverse EffectsAlzheimer&AposAnalogBehavioralLigandsSchizophreniaDrug DesignAnimalsGrantClinicInhibitor/AntagonistAreaAffinityBehavioral Assay
Grant awards (24)
Nonsense Suppressing Drugs for Rett Syndrome$282,726
R43 · FY2018 · NS · contact PI
Study of the New HDAC6i SW-100 as a Treatment for Alzheimerâs Disease and Other Tauopathies$392,663
R41 · FY2017 · AG · contact PI
Optimization of HDAC6 Inhibitors in the Treatment of CMT$352,668
R01 · FY2017 · NS · contact PI
AN HDAC6 APPROACH TO RETT SYNDROME$300,000
R43 · FY2017 · HD · contact PI
Optimization of HDAC6 Inhibitors in the Treatment of CMT$384,147
R01 · FY2016 · NS · contact PI
Optimizing Lead 5-HT2c Ligands for Use in the Treatment of Schizophrenia$670,441
R01 · FY2015 · MH · contact PI
Optimization of HDAC6 Inhibitors in the Treatment of CMT$377,734
R01 · FY2015 · NS · contact PI
Optimizing Lead 5-HT2c Ligands for Use in the Treatment of Schizophrenia$682,841
R01 · FY2014 · MH · contact PI
Optimization of HDAC6 Inhibitors in the Treatment of CMT$382,123
R01 · FY2014 · NS · contact PI
Design and Study of New Nicotinic Analogs for Use in Depression$819,419
U19 · FY2013 · MH · contact PI
Optimizing Lead 5-HT2c Ligands for Use in the Treatment of Schizophrenia$798,394
R01 · FY2013 · MH · contact PI
Optimization of HDAC6 Inhibitors in the Treatment of CMT$398,226
R01 · FY2013 · NS · contact PI
Design and Study of New Nicotinic Analogs for Use in Depression$861,780
U19 · FY2012 · MH · contact PI
Design and Study of New Nicotinic Analogs for Use in Depression$918,114
U19 · FY2011 · MH · contact PI
Molecular Interventions for Bipolar Disorder$440,898
R01 · FY2011 · MH · contact PI
Design and Study of New Nicotinic Analogs for Use in Depression$935,567
U19 · FY2010 · MH · contact PI
Chemistry and Biology of 5-HT2C Receptor Ligands for Drug Abuse$578,864
R01 · FY2010 · DA · contact PI
Molecular Interventions for Bipolar Disorder$445,322
R01 · FY2010 · MH · contact PI
Design and Study of New Nicotinic Analogs for Use in Depression$964,233
U19 · FY2009 · MH · contact PI
Chemistry and Biology of 5-HT2C Receptor Ligands for Drug Abuse$541,721
R01 · FY2009 · DA · contact PI
Molecular Interventions for Bipolar Disorder$438,905
R01 · FY2009 · MH · contact PI
Chemistry and Biology of 5-HT2C Receptor Ligands for Drug Abuse$523,155
R01 · FY2008 · DA · contact PI
Molecular Interventions for Bipolar Disorder$426,092
R01 · FY2008 · MH · contact PI
PKC Modulators for the Treatment of Alzheimer's disease$321,878
R01 · FY2008 · AG · contact PI